Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Indivior ( (GB:INDV) ) has issued an update.
Indivior PLC reported a 9% increase in net revenue for FY 2024, driven by strong performance of SUBLOCADE, which saw a 20% rise in net revenue. The company is focusing on streamlining operations to save over $100 million annually, reinvesting in long-term growth and its OUD assets, despite facing competitive pressures in the U.S. market. For FY 2025, Indivior expects a modest decline in SUBLOCADE revenue and a significant overall revenue drop due to intensified generic competition for SUBOXONE Film and the discontinuation of PERSERIS marketing. Despite these challenges, Indivior remains optimistic about achieving profitable growth and delivering value to shareholders by focusing on its key strategic objectives.
More about Indivior
Indivior PLC operates in the pharmaceutical industry, focusing primarily on addiction treatment therapies. The company’s main products include SUBLOCADE, a buprenorphine extended-release injection, and other opioid use disorder (OUD) treatments. Indivior aims to address opioid addiction challenges, primarily in the U.S. market, and is focused on expanding its pipeline and market presence in this sector.
YTD Price Performance: -15.23%
Average Trading Volume: 256,526
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £1.06B
For an in-depth examination of INDV stock, go to TipRanks’ Stock Analysis page.
